Overview

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer
Phase:
Phase 2
Details
Lead Sponsor:
Acerta Pharma BV
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Acalabrutinib
Pembrolizumab